Hongna Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hongna Sun has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Junnan Xu
Department of Medical Oncology, Liaoning Cancer Hospital & Institute Cancer Hospital of China Medical University Shenyang China
1 shared publication- Shuang Dai
Department of Medical Oncology, Cancer Center, West China Hospital Sichuan University Chengdu Sichuan China
1 shared publication - Tao Sun
Breast Internal Medicine Ward 1, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, China
1 shared publication Yiwen Ma
Department of Medical Oncology, Liaoning Cancer Hospital & Institute Cancer Hospital of China Medical University Shenyang China
1 shared publication
Latest Publications
- Open Access
- 13 July 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (2) , 1007-1024
Breast cancer brain metastasis: Current evidence and future directions
Breast cancer is the most common cancer in women and the second leading cause of cancer‐related deaths after lung cancer. Metastasis of the central nervous system is a terrible event for breast cancer patients, affecting their survival and quality of life. Compared with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative breast cancer patients, brain metastases are more likely to affect patients with triple‐negative breast cancer and human epidermal growth factor receptor 2‐positive breast cancer. The treatment of breast cancer has improved greatly in the last two decades. However, brain metastases from breast cancer remain the leading cause of morbidity and mortality. Patients with breast cancer brain metastasis have been in an inferior position due to the lack of clinical research in this field, and they are often explicitly excluded from almost all clinical trials. The occurrence and progression of brain metastases will result in severe cognitive impairment and adverse physical consequences, so we must have a good understanding of the molecular mechanisms of breast cancer brain metastasis. In this article, we have retrieved the latest literature of molecules and pathways associated with breast cancer brain metastasis, summarized common therapy strategies, and discussed the prospects and clinical implications of targeting the molecules involved.
- 13 July 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (2) , 1007-1024
Open AccessBreast cancer brain metastasis: Current evidence and future directions
Breast cancer is the most common cancer in women and the second leading cause of cancer‐related deaths after lung cancer. Metastasis of the central nervous system is a terrible event for breast cancer patients, affecting their survival and quality of life. Compared with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative breast cancer patients, brain metastases are more likely to affect patients with triple‐negative breast cancer and human epidermal growth factor receptor 2‐positive breast cancer. The treatment of breast cancer has improved greatly in the last two decades. However, brain metastases from breast cancer remain the leading cause of morbidity and mortality. Patients with breast cancer brain metastasis have been in an inferior position due to the lack of clinical research in this field, and they are often explicitly excluded from almost all clinical trials. The occurrence and progression of brain metastases will result in severe cognitive impairment and adverse physical consequences, so we must have a good understanding of the molecular mechanisms of breast cancer brain metastasis. In this article, we have retrieved the latest literature of molecules and pathways associated with breast cancer brain metastasis, summarized common therapy strategies, and discussed the prospects and clinical implications of targeting the molecules involved.